← Xencor, Inc. (XNCR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Xencor, Inc. (XNCR)
Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical company with ~250 employees and a $1.3B market cap, running a multi-asset pipeline led by XmAb5871 in Phase 2 for Systemic Lupus Erythematosus and vudalimab in Phase 2 across metastatic castration-resistant prostate cancer and ovarian cancer. The company is in acute financial distress with only $14.2M cash, a reported runway of ~0.6 months, and net debt of $94.4M as of mid-2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-31Data Readoutimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| XmAb5871 | Phase 2 | Systemic Lupus Erythematosus |
| vudalimab monotherapy | Phase 2 | Metastatic Castration-Resistant Prostate Cancer |
| vudalimab | Phase 2 | Ovarian Cancer |
| XmAb942 | Phase 2 | Ulcerative Colitis (UC) |
Price & technical context
3-month
+65.1%
6-month
+97.7%
12-month
+111.2%
52-wk range
$10.41–$29.30
vs 50-day MA
+2.9%
vs 200-day MA
+56.4%
Realized vol
65.3%
Max drawdown
-73.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XNCR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.